It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The ribosome-associated quality-control (RQC) pathway degrades aberrant nascent polypeptides arising from ribosome stalling during translation. In mammals, the E3 ligase Pirh2 mediates the degradation of aberrant nascent polypeptides by targeting the C-terminal polyalanine degrons (polyAla/C-degrons). Here, we present the crystal structure of Pirh2 bound to the polyAla/C-degron, which shows that the N-terminal domain and the RING domain of Pirh2 form a narrow groove encapsulating the alanine residues of the polyAla/C-degron. Affinity measurements in vitro and global protein stability assays in cells further demonstrate that Pirh2 recognizes a C-terminal A/S-X-A-A motif for substrate degradation. Taken together, our study provides the molecular basis underlying polyAla/C-degron recognition by Pirh2 and expands the substrate recognition spectrum of Pirh2.
Incompletely synthesized nascent polypeptides resulting from ribosome stalling during translation are under surveillance by ribosome-associated quality control. Here, the authors report the molecular mechanism by which the E3 ligase Pirh2 targets the polyalanine tail of aberrant nascent chains for degradation via the C-degron pathway.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Tianjin Medical University, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Haihe Laboratory of Cell Ecosystem, School of Basic Medical Sciences, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University, Department of Pharmacology, Tianjin Key Laboratory of Inflammatory Biology, Center for Cardiovascular Diseases, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
2 Tianjin Medical University, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Haihe Laboratory of Cell Ecosystem, School of Basic Medical Sciences, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University, Department of Biochemistry and Molecular Biology, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
3 Tianjin Medical University, Department of Biochemistry and Molecular Biology, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
4 Tianjin Medical University, Department of Immunology, Tianjin Institute of Immunology, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
5 Tianjin Medical University, Department of Medicinal Chemistry, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
6 Tianjin Medical University General Hospital, Department of Hepatobiliary Surgery, Tianjin, China (GRID:grid.412645.0) (ISNI:0000 0004 1757 9434)
7 Second Hospital of Tianjin Medical University, Department of Cardiology, Tianjin Institute of Cardiology, Tianjin, China (GRID:grid.412648.d) (ISNI:0000 0004 1798 6160)
8 Tianjin Medical University, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Haihe Laboratory of Cell Ecosystem, School of Basic Medical Sciences, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University, Department of Immunology, Tianjin Institute of Immunology, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
9 Tianjin Medical University, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Haihe Laboratory of Cell Ecosystem, School of Basic Medical Sciences, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University, Department of Biochemistry and Molecular Biology, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228); Tianjin Medical University General Hospital, Department of Hepatobiliary Surgery, Tianjin, China (GRID:grid.412645.0) (ISNI:0000 0004 1757 9434); Second Hospital of Tianjin Medical University, Department of Cardiology, Tianjin Institute of Cardiology, Tianjin, China (GRID:grid.412648.d) (ISNI:0000 0004 1798 6160)